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Pharmaceuticals in wastewater have clearly raised concern and a broad range of analytical methods has been used to 
assess the risk as accurately as possible. The aim of our study was to measure and compare the concentrations of atorvastatin, 
bisoprolol, carbamazepine, ciprofloxacin, clofibric acid, diclofenac, fluoxetine, metoprolol, and sertraline in wastewater 
samples taken from one municipal and one hospital wastewater treatment plant in Slovenia and to predict the potential 
environmental burden using the risk quotient. In both effluents only clofibric acid and fluoxetine were not detected. The 
measured concentrations of the remaining seven pharmaceuticals varied between the ng L-1 and the µg L-1 range. Hospital 
effluent showed higher concentrations, except for diclofenac and carbamazepine. However, high risk quotient was found 
only for ciprofloxacin and diclofenac in both municipal and hospital effluent. In conclusion, our method can provide a 
useful tool for systematic monitoring of pharmaceuticals commonly found in wastewater, which will enable a reliable 
assessment of the risks for the aquatic biota and humans. Knowing the risks will help to plan wastewater treatment and 
preserve our environment.
KEY WORDS: atorvastatin; bisoprolol; carbamazepine; ciprofloxacin; clofibric acid; diclofenac, fluoxetine; hospital; 
LC-MS/MS; metoprolol; municipal; risk assessment; sertraline
Pharmaceuticals in wastewater clearly pose a health 
risk to humans and aquatic life. First, they add to the 
growing problem of antimicrobial resistance caused by high 
and uncontrolled consumption of antibiotics and their 
continuous presence in the environment (1). Second, 
pharmaceutical residues in drinking water might disrupt the 
endocrine system. Endocrine disruptors may affect sperm 
count or cause breast and testicular cancer. One should bear 
in mind, however, that all evidence of direct adverse effects 
on human health is weak and inconclusive (2). On the other 
hand, the evidence of adverse effects on aquatic biota is 
much more convincing; long-term exposure to diclofenac 
impairs renal and gill function (3, 4), exposure to 
carbamazepine growth retardation (5), and exposure to 
sertraline reproductive disorders in a variety of fish species 
(6). Even though drug concentrations found in the 
environment are much lower than the therapeutic ones, 
some drugs, such as endocrine disruptors, can affect 
organisms even at extremely low concentrations. They may 
interfere with the endocrine system and affect vital functions 
such as development, reproduction, neurology, and 
immunity. Examples abound: intersex fish, synthesis of 
vitellogenin in males, feminisation, and absence of 
pregnancies (7, 8). Furthermore, lipophilic drugs and their 
metabolites tend to bioaccumulate (9).
A great many studies have introduced various 
monitoring methods in order to assess exposure and risk in 
non-target organisms as accurately as possible (9). 
Considering the increasing use of pharmaceuticals 
worldwide, their concentrations in the environment might 
reach toxicologically significant levels. There are two main 
approaches to evaluating environmental levels of a drug. 
The theoretical approach is based on factors such as 
consumption, metabolism, and excretion of these drugs. 
Estimating national drug consumption may be challenging, 
as the consumption of over-the-counter drugs is not as 
meticulously tracked as that of prescription drugs (10). 
Moreover, ingested drugs undergo biochemical reactions 
and their metabolites and degradation products could exhibit 
either the same or modified activity as the unaltered parent 
compound. In other words, evaluations may fail to reflect 
the true environmental load (11, 12). This is why it is 
imperative to apply the second, experimental approach, 
which employs sensitive analytical methods to accurately 
measure the concentrations of targeted compounds. For 
compounds present in the environment in trace 
concentrations an array of methods is available such as 
liquid or gas chromatography coupled with mass 
spectrometry (13-15) or enzyme-linked immunosorbent 
assay (ELISA) (15). Liquid chromatography coupled with 
tandem mass spectrometry (LC-MS/MS) in combination 
with a sample pre-concentration step seems to be the method 
of choice for most analytes (16). LC-MS/MS can determine 
a broad range of pharmaceuticals thanks to its high 
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sensitivity and selectivity in complex matrices such as 
wastewaters as well as better precision than with other 
analytical methods due to a less complicated sample 
preparation (e. g. no derivatisation is needed) (17).
One of the main reasons for pharmaceuticals entering 
bodies of water is low removal rate in wastewater treatment 
plants (WWTPs) (18-20). Because municipal WWTPs are 
considered the main route of pharmaceutical release into 
the aquatic environment, hospital effluents are frequently 
overlooked in exposure estimates. With this study we tried 
to address this oversight using the state-of-the art method. 
Our aim was (i) to measure the concentrations of eight 
common drugs and one metabolite from different classes 
that are released in Slovene wastewaters, (ii) to compare 
these concentrations between municipal and hospital 
wastewaters, and (iii) to assess environmental burden using 
the risk quotient.
MATERIALS AND METHODS
Our analysis targeted pharmaceuticals that are 
commonly used and well covered by literature data, namely 
atorvastatin, bisoprolol, carbamazepine, ciprofloxacin, 
clofibric acid, diclofenac, fluoxetine, metoprolol, and 
sertraline. Furthermore, their occurrence in wastewater has 
already been evidenced (21-24). Carbamazepine and 
clofibric acid were included due to their long history of use 
and persistence (25). Beta-blockers and NSAIDs were 
selected because of their widespread use (26). Diclofenac 
and bisoprolol are the 3rd and the 5th most prescribed drugs 
in Slovenia, respectively (27). In terms of ecotoxicity, 
carbamazepine, diclofenac, and metoprolol have been 
evidenced to cause growth retardation and heart 
abnormalities in fish embryos (28). Fluoxetine seems to 
cause endocrine-mediated reproduction dysfunction and 
developmental abnormalities, also in fish embryos (29, 30). 
Antibiotic residues in aquatic systems have clearly showed 
a potential to induce resistance in bacterial strains and 
become a serious threat for public health (31, 32).
Chemicals and reagents
Standards for carbamazepine (CAR), clofibric acid 
(CLO), diclofenac (DIC), fluoxetine (FLU), metoprolol 
(MET), and sertraline (SER) were purchased from Sigma-
Aldrich (Steinheim, Germany). Atorvastatin (ATOR) and 
bisoprolol fumarate (BIS) were purchased from Sequoia 
Researcher Products (Pangbourne, UK) and ciprofloxacin 
(CIP) from AppliChem GmbH (Darmstadt, Germany). The 
reagents used for standard and sample preparation including 
acetonitrile (ACN), acetic acid (98 %), formic acid (98-
100 %), methanol (MeOH), 2-propanol (iPrOH) and 
potassium dihydrogen phosphate were provided by Merck 
(Darmstadt, Germany). Ultra-pure water was produced by 
a Millipore Milli-Q water purification system A10 
Advantage (Millipore Corporation, Billerica, MA, USA). 
Solvents for LC-MS/MS analyses were LC-MS-grade 
acetonitrile ChromasolV® (Sigma-Aldrich, Steinheim, 
Germany), Milli-Q water and formic acid (98-100 %) 
Suprapur® (Merck, Darmstadt, Germany).
Sample collection
The samples were collected from two WWTPs in central 
Slovenia: one urban municipal WWTP with a capacity of 
9900 population equivalents and daily flow of approximately 
2200 m3 and the other WWTP serving a medium-sized 
hospital with 220 beds with a capacity of 1000 population 
equivalents and daily flow of approximately 40 m3. It also 
receives a negligible portion of wastewater from a nearby 
settlement. Both WWTPs employ a similar treatment: 
primary mechanical processing followed by biological 
treatment. Samples were collected both before the treatment 
point (influent) and after the final treatment (effluent). We 
obtained three litres of grab wastewater samples (influent 
or effluent) from each WWTP in accordance with the ISO/
IEC-17025 standard. Samples were stored at 4 °C and 
analysed within 24 h. From the municipal WWTP influent 
and effluent wastewater samples were taken in March and 
June 2015, and from the hospital WWTP five times at 
regular weekly intervals in May 2015. All wastewater 
samples had pH around 7.
Sample extraction and analysis
Standard stock solutions of each analyte were prepared 
by dissolving 5 mg of accurately weighed standard in 
methanol to obtain the concentration of 1 mg mL-1. The 
final concentration of the working solution of 1 mg L-1 was 
prepared by mixing the corresponding volumes of the stock 
solutions of each analyte and by diluting them further with 
ultra-pure water (standard mixture of pharmaceuticals).
To evaluate the concentration of pharmaceuticals in 
wastewater we employed the method of standard addition 
(33). The wastewater samples (250 mL) were first diluted 
with 250 mL of 250 mmol L-1 potassium dihydrogen 
phosphate buffer at pH 3. One aliquot of diluted sample 
was extracted without any additions in order to determine 
the original concentrations of the analytes. To other aliquots 
we added the appropriate amounts of the standard mixture 
of pharmaceuticals before extraction to obtain the final 
concentrations of 200, 500, 1000, and 2000 ng L-1. All 
samples were prepared in triplicate. Analyte concentrations 
were calculated using the linear regression curve.
All samples were extracted using a semi-automated 
sample preparation system SPE-DEX (Horizon Technology, 
Salem, NH, USA) with HLB Horizon discs. Rough samples 
were sequentially treated using a pre-developed method 
programmed in the EnvisionTM platform Controller software 
(Horizon Technology). Of all tested rinse solvents, a mixture 
of ACN (50 %), MeOH (25 %), and iPrOH (25 %) provided 
the best results.
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The obtained samples were analysed with the Agilent 
1290 Infinity LC coupled to Agilent 6460 triple quadrupole 
mass spectrometer (Agilent Technologies, Santa Clara, CA, 
USA). One microlitre of the sample was injected onto a 
100×3.0 mm, 2.7 µm Poroshell EC-C18 column (Agilent 
Technologies, Palo Alto, CA, USA) at 50 °C and eluted 
with mobile phase A (0.1 % formic acid in water) and B 
(ACN) using the following linear gradient (time min; % B; 
flow-rate mL min-1): (0;5;0.35), (0.5;5;0.35), (1.1;9;0.35), 
(1.2;40;0.65), (1.3;50;0.65), (2.0;60;0.65), (2.5;60; 0.65). 
Run time was 3.2 min. After each injection, the sampling 
need le  was  washed  wi th  a  wash ing  so lven t 
(MeOH:H2O=80:20 v/v). For MS, a JetStream
® (Agilent 
Technologies, Santa Clara, CA, USA) electrospray source 
was used. Instrument parameters were set as follows: drying 
gas temperature 275 °C, drying gas flow 5 L min-1, nebuliser 
45 psi, sheath gas temperature 320 °C, sheath gas flow 11 
L min-1, capillary entrance voltage 4000 V, nozzle voltage 
1000 V. Quadrupoles Q1 and Q3 were set at a wide mass 
resolution (1.2 amu). Instrument control, data acquisition, 
and quantification were performed by MassHunter 
Workstation software (Agilent Technologies, Santa Clara, 
CA, USA). The MRM transitions and other quantification 
settings for analytes are presented in Table 1.
Quality control
The analytical method was validated using five 
calibration standards (in triplicate) in the concentration 
range between 0.01-10 µg L-1. Process efficiency was 
assessed on samples of ultra-pure water and the June 
samples of the municipal WWTP influent and effluent 
wastewater spiked with the standard mixture of 
pharmaceuticals at different concentrations. The values 
were estimated by comparison of the peak area obtained 
from extracted sample and standard solution at the same 
final concentration (Eq. 1). The imprecision was expressed 
in terms of the relative standard deviation (RSD) of six 
replicates. The limit of quantification was defined as the 
concentration level with a signal to noise ratio of at least 
10:1. The influence of the sample matrix on analyte response 
was determined as an absolute matrix effect (ME) according 
to equation 2, based on Matuszewski et al. (34). The 
rationale of the equation will be described in a separate 
publication (manuscript in preparation). Values >0 indicate 





Environmental risk was assessed in terms of each 
compound's RQ, by calculating the ratio between measured 
environmental concentration (MEC) and the predicted no-
effect concentration (PNEC) according to Eq. 3. PNEC 
values were based on previously reported acute toxicity 
data for the most sensitive species (Table 4). A commonly 
accepted risk ranking criterion was used: RQ<0.1 means 
minimal risk to aquatic organisms, 0.1≤RQ<1 moderate 
risk, and RQ≥1 high risk (35, 36).
RESULTS AND DISCUSSION
Analytical method validation
Table 2 shows the process efficiencies, imprecision, and 
matrix effects, quantified in ultrapure and/or in influent and 
effluent wastewater. Process efficiencies were 81-106 %, 
68-102 %, and 73-99 % for ultrapure, influent, and effluent 
wastewater, respectively. Lower recoveries in wastewater 
Table 1 Quantification settings
Analyte MRM (m/z) CE (eV) Fr (V) P
atorvastatin 559.3 > 440.2 17 180 +
bisoprolol 326.2 > 116.1 9 144 +
carbamazepine 237.1 > 194.1 13 100 +
ciprofloxacin 332.1 > 314.1 16 134 +
clofibric acid 213.0 > 127.0 10 80 -
diclofenac 296.0 > 214.0 15 55 +
fluoxetine 310.1 > 148.1 1 100 +
metoprolol 268.2 > 116.0 12 96 +
sertraline 306.1 > 158.9 24 60 +
MRM: multiple-reaction monitoring; CE: collision energy; Fr: fragmentor; P: polarity
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samples are probably related to sample complexity. 
Imprecision expressed as RSD (%) of six samples spiked 
at 0.5 µg L-1 in all types of water was not higher than 12 % 
and, not surprisingly, the most complex water sample, 
influent wastewater had the highest RSD.
Calibration curves were linear with determination 
coefficients greater than 0.999 for all compounds. The 
linearity using the standard addition method was also 
confirmed for all analytes. The matrix effects were below 
2.5 %, except for ciprofloxacin. Limits of quantification 
(LOQ) for the investigated compounds were in the 
low ng L-1 range. Based on the validation data we concluded 
that the applied method was appropriate for further 
investigation of pharmaceuticals in wastewater.
Pharmaceutical concentrations in municipal wastewater
To the best of our knowledge, this the first study 
reporting pharmaceuticals in Slovene municipal and 
hospital wastewaters, but their concentrations in tap and 
river water have already been reported (37). Table 3 shows 
municipal wastewater influent and effluent concentrations 
of the selected compounds and detection frequencies. Six 
out of nine pharmaceuticals were detected at every sampling 
and one (atorvastatin) was found in 75 % of the samples. 
Clofibric acid, an active metabolite of the lipid-modifying 
drug clofibrate, and fluoxetine were not detected in any of 
the samples. This does not surprise, since both drugs have 
become quite obsolete and have been replaced by safer 
alternatives such as HMG CoA reductase inhibitors (statins) 
or new-generation selective serotonin reuptake inhibitors 
(sertraline, escitalopram, and paroxetine). Instead of 
clofibrate we found its alternative atorvastatin and instead 
of fluoxetine we found sertraline in both influent and 
effluent wastewater.
The concentrations of the remaining pharmaceuticals 
were mostly similar with other reports (38). Higher 
ciprofloxacin concentrations were reported in Italy 
(630 ng L-1) (10) and Spain (2200 ng L-1) (39). High 
concentrations of the nonsteroidal anti-inflammatory drug 
diclofenac in our study seem to confirm its ranking as the 
third most prescribed medicine in Slovenia (27). Another 
reason for its high concentration may be poor elimination 
efficiency via activated sludge, as reported earlier (21, 40, 
41). The highest measured absolute concentration reported 
in literature is 11 µg L-1 (9), while generally, its concentrations 
vary from a few ng L-1 up to 5.5 µg L-1, depending on the 
country and wastewater treatment technology (42-44).
The comparison between influent and effluent 
concentrations in our study clearly demonstrates insufficient 
removal rates for all monitored compounds. Another 
curiosity worth noting is that diclofenac effluent 
concentrations (that is to say, after treatment) were higher 
than influent concentrations in both March and June 
samples. This phenomenon may be closely related to 
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Table 3 Concentrations (ng L-1) and frequency (%) of pharmaceuticals in the municipal WWTP samples
Analyte Freq. (%)
Influent concentration (ng L-1) Effluent concentration (ng L-1)
March June March June
ATOR 75 < LOQ 23.3 < LOQ nd
BIS 100 130.1 77.5 216.4 36.0
CAR 100 269.6 193.8 482.4 340.5
CIP 100 135.4 165.8 101.9 < LOQ
CLO 0 nd nd nd nd
DIC 100 881.1 4056.9 1155.8 4760.0
FLU 0 nd nd nd nd
MET 100 12.5 18.8 67.4 25.0
SER 100 48.9 49.6 29.1 24.9
nd: not detected; <LOQ: below the limit of quantification
Figure 1 Concentrations of pharmaceuticals detected in the hospital WWTP effluent wastewater over five consecutive weeks in May 
2015. CIP and DIC are shown on the separate numeric scale. ATOR: atorvastatin; BIS: bisoprolol; CAR: carbamazepine; CIP: 
ciprofloxacin; DIC: diclofenac; MET: metoprolol; SER: sertraline
Figure 2 Comparison between the mean concentrations of pharmaceuticals detected in municipal WWTP (A) and hospital WWTP (B) 
effluents. ATOR: atorvastatin; BIS: bisoprolol; CAR: carbamazepine; CIP: ciprofloxacin; DIC: diclofenac; MET: metoprolol; SER: 
sertraline
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glucuronide and sulphate conjugates of diclofenac may be 
cleaved by enzymes during wastewater treatment and 
convert to their parent compound (42, 46). Moreover, the 
results from the evaluation of the matrix effect in influent 
and effluent wastewater (Table 2) exclude the potential 
analytical error (47).
Pharmaceutical concentrations in hospital wastewater and 
the comparison between municipal and hospital 
concentrations
In order to avoid daily bias for hospital wastewater 
composition we measured them weekly over entire May 
2015 (five samplings). Figure 1 shows their concentrations. 
Again, clofibric acid and fluoxetine were not detected, quite 
likely because of the same reason as for the municipal 
wastewater: these two obsolete drugs have been replaced 
by new ones. Concentrations of atorvastatin, metoprolol, 
and sertraline were roughly consistent across all five 
samplings, while bisoprolol and carbamazepine showed a 
higher variability. The highest and the most variable 
concentrations were observed for ciprofloxacin (0.7-
3.6 µg L-1) and diclofenac (1.1-3.2 µg L-1), yet ciprofloxacin 
concentrations in our study were slightly lower than in some 
other hospital wastewater studies (35, 48). Diclofenac 
concentrations, in turn, were between the ranges reported 
by Oliveira et al. (0.03-0.2 µg L-1) (37) and Lin and Tsai 
(up to 70 µg L-1) (49). All in all, our findings are in line with 
other published hospital wastewater studies (35), and 
confirm differences in the loading patterns for specific 
pharmaceuticals, depending on several factors reported 
earlier (37, 50). We believe that further investigation should 
look into these loading patterns.
The comparison between the municipal and hospital 
wastewater shows that hospital effluents contained 
pharmaceuticals in 1.5 to 24 times higher concentrations, 
except for diclofenac and carbamazepine (Figure 2). The 
greatest difference concerns the antibiotic ciprofloxacin, 
which is not surprising, due to far more intense use of 
antibiotics among hospitalised patients. In contrast, 
diclofenac concentrations were 1.6 times higher in 
municipal wastewater effluents. One of the reasons could 
be that the nonsteroidal anti-inflammatory drug diclofenac 
is not as common among hospitalised patients as in 
outpatients and the ageing population with musculoskeletal 
disorders.
In terms of environmental threat one should bear in 
mind that effluent concentrations were measured directly 
at the outlet and that wastewater gets significantly diluted 
before it reaches surface waters. Therefore, we expect that 
even the highest concentrations measured in our study 
should drop below the predicted critical downstream 
concentrations reported by Fick et al. (51). This does not 
mean that we should neglect the potential environmental 
threat of ciprofloxacin, diclofenac, or carbamazepine.
Environmental risk assessment
Our findings do not provide grounds for a precise risk 
assessment due to the low number of samples and the nature 
of grab sampling. However, they may give a general idea 
of the risk. We calculated the risk quotient for the lowest 
and highest measured concentrations and expressed it as a 
range. To do that we used previously reported PNECs for 
the most sensitive species (52-57) and combined them with 
the highest MECs to establish the worst-case scenario. Table 
4 shows high risk for only two compounds: ciprofloxacin 
and diclofenac. Both belong to therapeutic classes 
(antibiotics and NSAIDs, respectively) categorised as 
environmental hazards (58). When the risk quotient is higher 
than 1 (as is the case with these two drugs) the threat to 
exposed organisms is serious. Permanent presence of 
antibiotics in the environment leads to antimicrobial 
resistance (36). Even the WWTP sludge that retains about 
70 % of the influent concentration is known to be used as 
a fertiliser and can seriously affect the human food chain 
(59). Global studies have demonstrated that almost all 
bacterial species have become resistant to fluoroquinolone. 
Neisseria gonorrhoeae  has  rapidly developed 
fluoroquinolone resistance, which is now as high as 100 % 
in Asia and 10-30 % in Europe and North America (1). 
While ciprofloxacin poses a risk in terms of long-term 
exposure, diclofenac's toxicity is both acute and chronic in 
Daphnia. Long term exposure, in turn, leads to renal and 
gill function impairment in several fish species (3, 4). 
Furthermore, diclofenac residues have virtually destroyed 
the Pakistani vulture population (Gyps bengalensis) due to 
renal failure and visceral gout, as it fed on dead domestic 
livestock treated with diclofenac (60).
The risk quotient for carbamazepine and sertraline 
ranged between 0.1 and 1 in our study, which implies 
moderate environmental risk. Exposure to carbamazepine 
in an early life stage can slow down growth in Danio rerio 
(61). Sertraline as one of the most active selective serotonin 
re-uptake inhibitors may affect the nervous and/or hormonal 
systems of non-target organisms, such as the ones reported 
in Ceriodaphnia dubia (6). While our findings should not 
raise immediate concern if we look separately at the levels 
of each drug, the mixture of these pharmaceuticals may 
pose a far greater risk than either compound individually 
(52, 61).
CONCLUSION
This leads us to the shortcomings of our research. In 
addition to suboptimal sampling method and the modest 
number of samples mentioned above, it lacks experimental 
toxicology data about the exposed organisms and 
information about downstream (diluted) concentrations 
measured in surface water. Even so, our findings do confirm 
that antibiotics and NSAIDs are the most hazardous drug 
classes regardless of the source of wastewater, as reported 
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- A review. Sci Total Environ 2012;429:123-55. doi: 
10.1016/j.scitotenv.2012.04.028
10. Verlicchi P, Al Aukidy M, Jelic A, Petrović M, Barceló D. 
Comparison of measured and predicted concentrations of 
selected pharmaceuticals in wastewater and surface water: a 
case study of a catchment area in the Po Valley (Italy). Sci 
Total Environ 2014;470-471:844-54. doi: 10.1016/j.
scitotenv.2013.10.026
11. Celiz MD, Tso J, Aga DS. Pharmaceutical metabolites in the 
environment: analytical challenges and ecological risks. 
Environ Toxicol Chem 2009;28:2473-84. doi: 10.1897/09-
173.1
12. Evgenidou EN, Konstantinou IK, Lambropoulou DA. 
Occurrence and removal of transformation products of PPCPs 
and illicit drugs in wastewaters: a review. Sci Total Environ 
2015;505:905-26. doi: 10.1016/j.scitotenv.2014.10.021
13. Castiglioni S, Bagnati R, Calamari D, Fanelli R, Zuccato E. 
A multiresidue analytical method using solid-phase extraction 
and high-pressure liquid chromatography tandem mass 
spectrometry to measure pharmaceuticals of different 
therapeutic classes in urban wastewaters. J Chromatogr A 
2005;1092:206-15. doi: 10.1016/j.chroma.2005.07.012
14. Robles-Molina J, Gilbert-López B, García-Reyes JF, Molina-
Díaz A. Monitoring of selected priority and emerging 
contaminants in the Guadalquivir River and other related 
surface waters in the province of Jaén, South East Spain. Sci 
Total Environ 2014;479-480:247-57. doi: 10.1016/j.
scitotenv.2014.01.121
earlier (35). Our method can serve as a preliminary tool for 
monitoring pharmaceutical compounds in wastewater, as 
it allows expanding from a small to a large number of 
compounds. We believe that with a substantial number of 
samples this method can provide enough information for a 
relevant and reliable risk assessment.
However, in light of these findings, we believe that 
wastewater treatment should include new technologies of 
hazardous compound removal. For instance, diclofenac is 
significantly better eliminated by oxidative treatment with 
ozone or hydrogen peroxide (62), and replacing activated 
sludge with attached-growth biomass has also shown 
promising effects (40).
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Koncentracije zdravilnih učinkovin v slovenskih komunalnih in bolnišničnih odpadnih vodah:  
preliminarna raziskava
Pojavljanje ostankov zdravilnih učinkovin v odpadnih vodah postaja vedno bolj aktualna tematika in posledično se širi 
nabor analiznih metod, ki omogočajo natančno ugotavljanje njihove prisotnosti in služijo kot orodje za napovedovanje 
tveganja teh onesnažil v vodnem okolju. Namen naše raziskave je bil kvantitativno ovrednotiti prisotnost izbranih zdravilnih 
učinkovin (atorvastatin, bisoprolol, ciprofloksacin, diklofenak, fluoksetin karbamazepin, klofibrinska kislina, metoprolol 
in sertralin) na iztoku ene komunalne in ene bolnišnične čistilne naprave. Na osnovi meritev koncentracij smo z uporabo 
količnika tveganja ocenili okoljsko breme vključenih spojin. Ugotovili smo prisotnost sedmih zdravilnih učinkovin, 
medtem ko klofibrinske kisline in fluoksetina nismo zaznali v nobenem vzorcu. Izmerjene koncentracije so bile v širokem 
koncentracijskem območju (od ng L-1 do µg L-1), praviloma višje v bolnišnični odpadni vodi, z izjemo diklofenaka in 
karbamazepina. Izračunan količnik tveganja nakazuje na visoko tveganje za ciprofloksacin in diklofenak v vseh analiziranih 
vzorcih odpadnih voda. Raziskava je pokazala, da je razvita metoda primerno orodje za nadaljnje študije, ki bodo na 
podlagi sistematičnega spremljanja teh novodobnih onesnažil v odpadnih vodah omogočile zanesljivejšo oceno tveganja 
za izpostavljene vodne organizme in tudi za zdravje ljudi. Poznavanje teh tveganj bo prispevalo k načrtovanju ustrezne 
tehnologije čiščenja odpadnih voda in posledično k ohranjanju čistega in zdravega okolja.
KLJUČNE BESEDE: atorvastatin; bisoprolol; bolnišnična čistilna naprava; ciprofloksacin; diklofenak; fluoksetin; 
karbamazepin; klofibrinska kislina; komunalna čistilna naprava; LC-MS/MS; metoprolol; ocena tveganja; sertralin
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